Seventure Partners today announces the trade sale of its portfolio company Cambrooke Therapeutics, MA, US, to Ajinomoto.
Paris, France – 10 November 2017 – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces the trade sale of its portfolio company Cambrooke Therapeutics, MA, US, to Ajinomoto Co., Inc.. This represents the first transactional exit from Seventure’s healthcare and nutrition-focused investment vehicle, Health For Life Capital™.
Cambrooke is a global leader and innovator in therapeutic nutrition for inborn errors of metabolism and ketogenic diet. Cambrooke’s product portfolio serves the needs of people with chronic health conditions, who are reliant on Medical Foods and specialized functional foods as a central component of their daily nutritional needs. With this acquisition, Cambrooke gains access to Ajinomoto’s global nutrition and ingredient sciences expertise and will continue leading the field of therapeutic nutrition solutions for chronic health conditions. It will also be able to continue serving its customers’ lifestyle needs, now with expanded reach and R&D capabilities.
Cambrooke President and Chief Executive Officer Howard Lossing states that “Ajinomoto is a worldwide leader in amino acids, pharmaceuticals, high-quality seasonings, processed foods, beverages, and specialty chemicals. Ajinomoto’s corporate motto of ‘Eat Well, Live Well.’ is an elegant statement that directly reflects Cambrooke’s mission of improving lives via providing the most delicious and most nutritious Medical Foods for people with chronic health conditions.”
Seventure Partners have led the latest investment round into Cambrooke, joined by returning backers Galen Partners and has leveraged its extensive industry knowledge and expertise to support company international and product portfolio expansion efforts.
Isabelle de Cremoux, CEO of Seventure Partners and founder of Health for Life Capital™ states: “Health for Life Capital™‘s continued success, as realized by Cambrooke’s trade sale, generating an IRR of over 55% for this transaction, has shown the value of a highly specialized nutrition and healthcare investment vehicle. We are delighted for Cambrooke and look forward to seeing the Company’s continued success.”
